Validation of the International Working Group Proposal for SF3B1 Mutant Myelodysplastic Syndromes.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021010831
Abstract: Komrokji et al examined the proposed international working group proposal to designate SF3B1-mutant myelodysplastic syndrome (MDS) as a unique disease entity, using a single-institution validation cohort of 1779 MDS patients, of whom 320 harbored SF3B1… read more here.
Keywords: mutant myelodysplastic; working group; international working; sf3b1 mutant ... See more keywords
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018604
Abstract: Myelodysplastic syndromes/neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and… read more here.
Keywords: higher risk; myelodysplastic syndromes; international working; response criteria ... See more keywords